SEC Filing Summary: Carlyle Group Inc. (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending September 30, 2024. The document discloses the equity securities held by the investment manager as of the end of the quarter. It does not contain financial performance data for Carlyle Group Inc. itself, but rather a snapshot of its investment portfolio.
Key Financial Metrics and Portfolio Holdings
The filing lists 25 equity positions. The following table summarizes the top holdings by value and share count based on the provided text:
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Quidelortho Corp | 8,260,183 | $376,664,345 | Sole |
| Soleno Therapeutics Inc | 4,071,562 | $205,369,587 | Sole |
| ZoomInfo Technologies Inc | 11,665,307 | $120,385,969 | Sole |
| Getty Images Holdings Inc | 9,212,799 | $35,100,766 | Sole |
| Phathom Pharmaceuticals Inc | 3,496,808 | $63,187,321 | Sole |
Note: The filing does not provide aggregate portfolio value, revenue, profit, cash flow, margins, debt, or liquidity metrics for Carlyle Group Inc. These figures are not applicable to a Form 13F filing.
Material Changes and Portfolio Composition
As a quarterly snapshot, this filing does not explicitly state material changes versus the prior period (June 30, 2024) within the text provided. However, the portfolio composition indicates a heavy concentration in:
- Biotechnology and Pharmaceuticals: Significant holdings in Quidelortho, Soleno Therapeutics, Phathom Pharmaceuticals, Adicet Bio, Jasper Therapeutics, Reneo Pharmaceuticals, and Spruce Biosciences.
- Technology and Software: Positions in ZoomInfo, Solarwinds, and Broadcom.
- Real Estate and Services: Holdings in Invitation Homes, CubeSmart, and Getty Images.
The "Other" column indicates some positions involve derivative instruments (Put/Call) or specific voting arrangements, such as Smart Sh Global Ltd which lists "2,3" in the other column.
Guidance, Risks, and Contingencies
The filing text does not contain management commentary, forward-looking guidance, or specific risk factors regarding Carlyle Group's operations. The standard SEC disclaimer states that the Commission has not reviewed the information for accuracy or completeness.
Key Facts for Investor Verification
- Top Concentration: Verify the valuation and recent performance of Quidelortho Corp, which represents the largest single position at approximately $376.7 million.
- Biotech Exposure: Assess the aggregate risk of the portfolio's significant exposure to the biotechnology sector, which includes multiple clinical-stage or specialized pharmaceutical companies.
- Voting Control: Confirm that Carlyle Group Inc. holds "Sole" voting authority for the majority of these positions, indicating direct control over voting decisions for these specific shares.
- Derivative Activity: Investigate the specific nature of the "Other" column entries (e.g., Smart Sh Global Ltd) to understand any associated derivative positions or complex voting structures.